Bulfone-Paus S - Search Results

1

Immunosuppression with an interleukin-2 fusion protein leads to improved LV function in experimental ischemic cardiomyopathy.

Koch M, Savvatis K, Scheeler M, Dhayat S, Bonaventura K, Pohl T, Riad A, Bulfone-Paus S, Schultheiss HP, Tschöpe C. Koch M, et al. Int Immunopharmacol. 2010 Feb;10(2):207-12. doi: 10.1016/j.intimp.2009.11.001. Epub 2009 Nov 6. Int Immunopharmacol. 2010. PMID: 19897056

2

Suppression of cell-mediated and humoral immune responses by an interleukin-2-immunoglobulin fusion protein in mice.

Kunzendorf U, Pohl T, Bulfone-Paus S, Krause H, Notter M, Onu A, Walz G, Diamantstein T. Kunzendorf U, et al. J Clin Invest. 1996 Mar 1;97(5):1204-10. doi: 10.1172/JCI118534. J Clin Invest. 1996. PMID: 8636431 Free PMC article.

3

Prolongation of corneal allograft survival by an interleukin-2-immunoglobulin fusion protein in mice.

Zhang EP, Pohl T, Bulfone-Paus S, Wachtlin J, Kunzendorf U, Hoffmann F. Zhang EP, et al. Graefes Arch Clin Exp Ophthalmol. 1998 Jul;236(7):486-92. doi: 10.1007/s004170050110. Graefes Arch Clin Exp Ophthalmol. 1998. PMID: 9672793

4

An interleukin-2-IgG-Fas ligand fusion protein suppresses delayed-type hypersensitivity in mice by triggering apoptosis in activated T cells as a novel strategy for immunosuppression.

Bulfone-Paus S, Rückert R, Krause H, von Bernuth H, Notter M, Pohl T, Tran TH, Paus R, Kunzendorf U. Bulfone-Paus S, et al. Transplantation. 2000 Apr 15;69(7):1386-91. doi: 10.1097/00007890-200004150-00030. Transplantation. 2000. Retraction in: Transplantation. 2011 Dec 27;92(12):e68. doi: 10.1097/TP.0b013e31824368a8 PMID: 10798759 Retracted.

5

Interleukin-15 protects from lethal apoptosis in vivo.

Bulfone-Paus S, Ungureanu D, Pohl T, Lindner G, Paus R, Rückert R, Krause H, Kunzendorf U. Bulfone-Paus S, et al. Nat Med. 1997 Oct;3(10):1124-8. doi: 10.1038/nm1097-1124. Nat Med. 1997. PMID: 9334724

6

Vaccination with tumor cells engineered to secrete interleukin 2-immunoglobulin G fusion protein induces tumor rejection.

Bulfone-Paus S, von Bernuth H, Rückert R, Wachtlin J, Ungureanu D, Notter M, Krause H, Pohl T, Paus R, Kunzendorf U. Bulfone-Paus S, et al. Cancer Res. 1998 Jul 1;58(13):2707-10. Cancer Res. 1998. PMID: 9661877

7

IL-15-IgG2b fusion protein accelerates and enhances a Th2 but not a Th1 immune response in vivo, while IL-2-IgG2b fusion protein inhibits both.

Rückert R, Herz U, Paus R, Ungureanu D, Pohl T, Renz H, Bulfone-Paus S. Rückert R, et al. Eur J Immunol. 1998 Oct;28(10):3312-20. doi: 10.1002/(SICI)1521-4141(199810)28:10<3312::AID-IMMU3312>3.0.CO;2-I. Eur J Immunol. 1998. PMID: 9808200 Free article.

8

Immunomodulation in experimental and clinical nephrology using chimeric proteins.

Kunzendorf U, Pohl T, Bulfone-Paus S, Krause H, Ziegler E, Onu A, Distler A. Kunzendorf U, et al. Kidney Blood Press Res. 1996;19(3-4):201-4. doi: 10.1159/000174074. Kidney Blood Press Res. 1996. PMID: 8887261 Review.

9

Inhibition of corneal allograft reaction by CTLA4-Ig.

Hoffmann F, Zhang EP, Pohl T, Kunzendorf U, Wachtlin J, Bulfone-Paus S. Hoffmann F, et al. Graefes Arch Clin Exp Ophthalmol. 1997 Aug;235(8):535-40. doi: 10.1007/BF00947013. Graefes Arch Clin Exp Ophthalmol. 1997. PMID: 9285225

10

Regulation of IL-15 secretion via the leader peptide of two IL-15 isoforms.

Onu A, Pohl T, Krause H, Bulfone-Paus S. Onu A, et al. J Immunol. 1997 Jan 1;158(1):255-62. J Immunol. 1997. PMID: 8977197

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

147 results

Search Page

Filters